0000899243-22-028418.txt : 20220811
0000899243-22-028418.hdr.sgml : 20220811
20220811205326
ACCESSION NUMBER: 0000899243-22-028418
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220809
FILED AS OF DATE: 20220811
DATE AS OF CHANGE: 20220811
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Beaulieu Joseph
CENTRAL INDEX KEY: 0001766032
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35945
FILM NUMBER: 221157516
MAIL ADDRESS:
STREET 1: C/O EPIZYME, INC.
STREET 2: 400 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Epizyme, Inc.
CENTRAL INDEX KEY: 0001571498
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261349956
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-229-5872
MAIL ADDRESS:
STREET 1: 400 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-09
0
0001571498
Epizyme, Inc.
EPZM
0001766032
Beaulieu Joseph
C/O EPIZYME, INC., 400 TECHNOLOGY
SQUARE, 4TH FLOOR
CAMBRIDGE
MA
02139
0
1
0
0
See Remarks
Common Stock, par value $0.0001
2022-08-09
4
M
0
300000
1.39
A
330963
D
Common Stock, par value $0.0001
2022-08-09
4
F
0
279864
1.39
D
51099
D
Stock Option (Right to Buy)
1.39
2022-08-09
4
M
0
300000
0.00
D
2032-03-16
Common Stock
300000
0
D
These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on August 9, 2022.
On June 27, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. Pursuant to the terms of the Merger Agreement, each Exercisable Pre-Close Option (as defined in the Merger Agreement) became exercisable on the Acceleration Date (August 5, 2022) up to and through the close of regular trading on the Nasdaq Stock Market on the second (2nd) business day thereafter (August 9, 2022).
Senior Vice President, Finance and Corporate Controller
/s/ John Weidenbruch, attorney-in-fact
2022-08-11